Market access risk in nephrology

Kidney disease unfolds slowly, which is the whole reimbursement problem. The outcomes that matter — dialysis, transplant, death — arrive years after a trial can run, so the field's drugs are approved on what can be measured now: protein in the urine, the rate at which kidney filtration declines. Payers have accepted those stand-ins with conditions, and are now facing a wave of new medicines in a single rare disease, IgA nephropathy, each approved on the same surrogate and each asking for its own price. Underneath sits the chronic kidney disease of millions, where the newest drugs are added on top of generics that already slow the decline. This page brings together MARA's independent assessments of reimbursement risk across the field; IgA nephropathy has its own deep-dive page beneath it.

What payers ask in nephrology

Does less protein in the urine mean a kidney saved? Proteinuria is the field's approval endpoint and the payer's first question. Health technology assessment bodies accept it as a stand-in only where the link to slower loss of kidney function is shown for that drug and that disease — and they reimburse conditionally, awaiting the filtration-rate data that takes years to mature.

What does the drug add on top of generics? Kidney protection already has a standard: blood-pressure medicines and the newer diabetes drugs, most of them cheap and taken by everyone with the disease. A new drug is reimbursed for what it adds on top of that baseline, in patients who are still declining despite it — a narrower group than the trial population.

How far away is the payoff? The economic case for a kidney drug rests on dialysis avoided a decade or more in the future. Payers discount that future heavily, question the models that project it, and ask for registries and re-assessment dates rather than paying today for a benefit the trial could not observe.

Five drugs, one rare disease, which price? IgA nephropathy went from no approved treatment to several in two years, with different mechanisms, different dosing and the prospect of combination. Payers ask where each sits, whether two can be reimbursed together, and what the whole regimen costs — the price of one drug is no longer the question.

The MARA record in nephrology

Nephrology holds seventeen dated assessments in the MARA catalogue: the new classes in IgA nephropathy, autosomal dominant polycystic kidney disease, chronic kidney disease with and without diabetes, anaemia of kidney disease, the itch of dialysis, hyperkalaemia, transplant desensitisation and childhood nephrotic syndrome. Each report answers the same payer questions, carries its "as of" date, and stays on the record — when the evidence moves, a newer vintage replaces the older one visibly, never silently. Assessments are produced on MARA's own initiative for awareness; the current MARA Rating for any drug is available on request.

Deep-dive: Market access risk in IgA nephropathy

Current assessments (17)

Selected commentary

Sibeprenlimab / Voyxact: the trial measured protein in the urine. Payers need to know about kidneys.

For how a MARA Rating is built, see the methodology and what a MARA Rating is. To request the current rating for any drug in this area, use the contact form.